Sartorius Stedim Biotech SA banner

Sartorius Stedim Biotech SA
PAR:DIM

Watchlist Manager
Sartorius Stedim Biotech SA Logo
Sartorius Stedim Biotech SA
PAR:DIM
Watchlist
Price: 156.7 EUR 3.43% Market Closed
Market Cap: €15.3B

P/FCFE

-234.5
Current
2 618%
Cheaper
vs 3-y average of 9.3

Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.

P/FCFE
-234.5
=
Market Cap
€15.8B
/
Free Cash Flow to Equity
€-65m

Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.

P/FCFE
-234.5
=
Market Cap
€15.8B
/
Free Cash Flow to Equity
€-65m

Valuation Scenarios

Sartorius Stedim Biotech SA is trading above its 3-year average

If P/FCFE returns to its 3-Year Average (9.3), the stock would be worth €-6.22 (104% downside from current price).

Statistics
Positive Scenarios
0/4
Maximum Downside
-193%
Maximum Upside
No Upside Scenarios
Average Downside
129%
Scenario P/FCFE Value Implied Price Upside/Downside
Current Multiple -234.5 €156.7
0%
3-Year Average 9.3 €-6.22
-104%
5-Year Average 34.4 €-22.96
-115%
Industry Average 217.1 €-145.08
-193%
Country Average 15 €-10
-106%

Forward P/FCFE
Today’s price vs future free cash flow to equity

Not enough data available to calculate forward P/FCFE

Peer Comparison

All Multiples
P/FCFE
P/E
All Countries
Close
Market Cap P/FCFE P/E
FR
Sartorius Stedim Biotech SA
PAR:DIM
15.2B EUR -234.5 56.8
US
PerkinElmer Inc
LSE:0KHE
936.1B USD 2 167.8 3 881
US
Thermo Fisher Scientific Inc
NYSE:TMO
178B USD 12.2 25.5
US
Danaher Corp
NYSE:DHR
126.6B USD 19.4 33.7
KR
Samsung Biologics Co Ltd
KRX:207940
82.3T KRW 190.3 46.1
CN
WuXi AppTec Co Ltd
SSE:603259
326.9B CNY 21.5 17.1
CH
Lonza Group AG
SIX:LONN
32.9B CHF -40.7 -119.6
US
Agilent Technologies Inc
NYSE:A
32.7B USD 36.6 25.2
US
Waters Corp
NYSE:WAT
30.3B USD 106.8 46.8
US
IQVIA Holdings Inc
NYSE:IQV
26.9B USD 9.7 19.7
US
Mettler-Toledo International Inc
NYSE:MTD
26B USD 31.7 29.7

Market Distribution

Lower than 100% of companies in France
Percentile
0th
Based on 1 206 companies
0th percentile
-234.5
Low
0.1 — 8.4
Typical Range
8.4 — 26.7
High
26.7 —
Distribution Statistics
France
Min 0.1
30th Percentile 8.4
Median 15
70th Percentile 26.7
Max 1 133.8

Sartorius Stedim Biotech SA
Glance View

Sartorius Stedim Biotech SA has been weaving the intricate threads of biotechnology innovation into a fabric of global influence and success. Established as a pivotal player in the biopharmaceutical industry, Sartorius Stedim Biotech has carved out a niche by offering sophisticated products and solutions that cater to the unique needs of biopharmaceutical manufacturers. The company’s portfolio is a testament to the fusion of scientific ingenuity and relentless pursuit of quality. Spanning filtration and purification solutions, fermentation equipment, and fluid management systems, their offerings ensure that complex biological drugs, including vaccines and monoclonal antibodies, are produced efficiently and safely. Sartorius Stedim Biotech’s endeavor is not just about supplying equipment; it’s about providing integrated solutions that optimize the entire production process, ensuring consistency, scalability, and compliance in industries bound by strict regulatory oversight. The company generated revenue through its comprehensive range of products and services that address every step of the biomanufacturing process. Their business model hinges on fostering long-term relationships with clients by offering tailored solutions that enhance productivity and reduce time-to-market for new therapies. Beyond direct sales of high-value equipment, Sartorius Stedim Biotech also capitalizes on recurring revenue streams generated from consumables and maintenance services essential for the ongoing operation of their systems. By continuously innovating and expanding its product lines, the company stays at the forefront of technological advancements, enabling clients to tackle the ever-evolving challenges of bioproduction. As the global biopharmaceutical industry surges forward, driven by increasing demand for biologics, Sartorius Stedim Biotech remains poised to maintain its role as an indispensable ally to firms dedicated to transforming the health landscape through revolutionary therapies.

DIM Intrinsic Value
138.44 EUR
Overvaluation 12%
Intrinsic Value
Price €156.7
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett